Enterprise of Rosatom State Corporation
Print version

Industry news

13/05/2014
ANSTO National Medical Facility to Triple Production of Radiopharmaceuticals

ANM project at ANSTO will benefit the Australian health industry and position Australia as a global leader in the high-end manufacturing of nuclear medicine.

13/05/2014
Areva 2014 1at Quarter Revenue

AREVA's operations generated consolidated revenue of 1.781 billion euros in the first quarter of 2014, a decrease of 18.1% (-17.3 % like for like) compared with the same period in 2013.

13/05/2014
Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance

Mallinckrodt plc a leading global specialty pharmaceutical company, today reported results for the second quarter of fiscal 2014, which ended March 28, 2014.

11/03/2014
FDA, EMA Grant Orphan Drug Status to Gallium-68 Dotatate Radiopharmaceutical

Advanced Accelerator Applications (AAA), a growing international player in molecular nuclear medicine, announced they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 Dotatate.

04/03/2014
Update on Mo-99 Availability

The ongoing Molybdenum-99 (Mo-99) supply challenges faced by the nuclear medicine industry remain in effect. Based on currently available resources and projections for Mo-99 supply, generator standing orders should be met throughout March.

04/03/2014
NRU Reactor Scheduled for Maintenance in April, Disrupting Mo-99 Supply

The NRU reactor is scheduled to enter into its maintenance April 13, and anticipates restarting May 13, with resumption of their Mo-99 supply on May 17.

04/03/2014
AREVA Group Chooses Caen (France) as the Location for Its Second Lead-212 Production Facility

Luc Oursel, President of AREVA, announced the selection of the Caen la Mer urban community (Calvados, France) as the location for its second lead-212 production facility.

04/03/2014
Priority Review Given for the Expanded Use of Lymphoseek (Technetium-99m Tilmanocept) Injection

Navidea Biopharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA) and granted a Priority Review for the expanded use of Lymphoseek (technetium 99m tilmanocept) Injection.

17/02/2014
Worldwide Medical Imaging Reagents Market on the Rise

The global market for medical reagents, including those used for molecular imaging purposes, is expected to grow substantially through 2016.

04/02/2014
Update on Mo-99 Availability

The ongoing Molybdenum-99 (Mo-99) supply challenges faced by the nuclear medicine industry remain in effect. Based on currently available resources and projections for Mo-99 supply next month, generator standing orders should be met throughout February.